

# **HLA Typing Kits**

## **Instructions for Use**

PCR Amplification and Sequencing of HLA Class I and II Loci

Version No: 1.0 Issue Date: Oct 2017

For Research Use Only. Not for use in diagnostic procedures. No claim or representation is intended to provide information for the diagnosis, prevention, or treatment of a disease.



CareDx Pty Ltd 20 Collie St. Fremantle 6160 Western Australia Australia

## **Contents**

PRINCIPLE	3
KIT COMPOSITION	4
STORAGE REQUIREMENTS	9
MATERIALS, REAGENTS AND EQUIPMENT NOT SUPPLIED	
SAMPLE REQUIREMENTS	
WARNINGS AND SAFETY PRECAUTIONS	
PROCEDURE	12
1. PCR	12
2. AGAROSE GEL ELECTROPHORESIS	
3. PURIFICATION OF PCR PRODUCT	13
4. SEQUENCING REACTION	
5. PURIFICATION OF SEQUENCING REACTION PRODUCTS	
6. DENATURATION & ELECTROPHORESIS OF SEQUENCING REACTION PRODUCTS	
7. EDITING AND ANALYSIS OF ELECTROPHEROGRAMS	17
PERFORMANCE CHARACTERISTICS	17
LIMITATIONS AND CAUTIONS	18
LICENSE	18
BIBLIOGRAPHY	18
TROUBLESHOOTING	19
RELATED PRODUCTS	
OLERUP SBT <sup>TM</sup> HARPS <sup>®</sup>	
OLERUP SBT <sup>TM</sup> HLA TYPING KITS	21
CONTACT INFORMATION	22
MANUFACTURER	22
METHOD HISTORY	22
AUTHORSHIP AND APPROVALS	22

## **Principle**

The HLA Sequencing Based Typing (SBT) procedure described here was originally developed by D. Sayer in 2001¹ and developed into a single tube assay in 2004². The procedure involves the initial amplification of the target sequence followed by enzymatic treatment to remove unincorporated primers and dNTPs. The amplicon is then used as a template for direct automated fluorescent DNA sequencing using customized sequencing primers and the Big Dye® Terminator sequencing chemistry available from Applied Biosystems<sup>TM</sup> by Life Technologies<sup>TM</sup>. The extension products are purified according to the ethanol precipitation method and denatured using Hi-Di<sup>TM</sup> formamide available from Applied Biosystems<sup>TM</sup> by Life Technologies<sup>TM</sup>, before separation and detection on an automated fluorescent DNA sequencer. It is recommended that the resulting data is then analysed with ASSIGN<sup>TM</sup> SBT sequence analysis software from CareDx Pty Ltd³-5.

**Kit Composition** 

Catalogue No	Σ	PRE-PCR Contents <sup>†</sup> (No of vials)			POST-PCR Con (No of vials	
	<u> </u>	`				,
XH-PD1.1-2(20)	20 tests	DNA POL – HLA-A	1 x 25μL	AEX1F	AEX1R	1 x 44μL each
		HLA-A MIX	1 x 352μL	AEX2F	AEX2R	
				AEX3F	AEX3R	
				AEX4F	AEX4R	
XH-PD1.1-2(50)	50 tests	DNA POL – HLA-A	1 x 60μL	AEX1F	AEX1R	1 x 110μL each
		HLA-A MIX	1 x 880μL	AEX2F	AEX2R	
				AEX3F	AEX3R	
				AEX4F	AEX4R	
BS-PD2.1-2(20)	20 tests	DNA POL – HLA-B	1 x 25μL	BEX1F	BEX2F	1 x 44μL each
		HLA-B MIX	1 x 352μL	BEX2R	BEX3F	
				BEX3R	BEX4F	
				BEX4R		
BS-PD2.1-2(50)	50 tests	DNA POL – HLA-B	1 x 60μL	BEX1F	BEX2F	1 x 110μL each
		HLA-B MIX	1 x 880μL		BEX3F	
				BEX3R	BEX4F	
				BEX4R		
	XH-PD1.1-2(20)  XH-PD1.1-2(50)  BS-PD2.1-2(20)	XH-PD1.1-2(20) 20 tests  XH-PD1.1-2(50) 50 tests  BS-PD2.1-2(20) 20 tests	XH-PD1.1-2(20)   20 tests   DNA POL - HLA-A   HLA-A MIX	XH-PD1.1-2(20)   20 tests   DNA POL - HLA-A   1 x 25μL   1 x 352μL     1 x 880μL     1 x 352μL       1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL       1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL     1 x 352μL       1 x 352μL       1 x 352μL       1 x 352μL	XH-PD1.1-2(20)   20 tests   DNA POL - HLA-A   1 x 25μL   AEX1F   AEX2F   AEX3F   AEX4F     XH-PD1.1-2(50)   50 tests   DNA POL - HLA-A   1 x 60μL   AEX1F   AEX2F   AEX3F   AEX4F     BS-PD2.1-2(20)   20 tests   DNA POL - HLA-B   1 x 25μL   BEX1F   AEX4F     BS-PD2.1-2(50)   50 tests   DNA POL - HLA-B   1 x 352μL   BEX2R   BEX3R   BEX4R     BS-PD2.1-2(50)   50 tests   DNA POL - HLA-B   1 x 60μL   BEX1F   BEX2R   BEX3R   BEX4R     BS-PD2.1-2(50)   50 tests   DNA POL - HLA-B   1 x 60μL   BEX1F   BEX2R   BEX3R   BE	XH-PD1.1-2(20)   20 tests   DNA POL - HLA-A   1 x 25μL   AEX1F   AEX2R   AEX2R   AEX3F   AEX3R   AEX4F   AEX4R   AEX4F   AEX4F   AEX4R   AEX4F   AEX4R   AEX4F   AE

Page 4 of 22 For Research Use Only

Kit	Catalogue No	Σ	PRE-PCR Cont (No of vials		P	OST-PCR Con (No of vials	
HLA-C	HH-PD3.2-2(20) HH-PD3.2-2(50)	20 tests 50 tests	DNA POL – HLA-C  DNA POL – HLA-C	1 x 25μL 1 x 352μL 1 x 60μL	CEX1F  CEX2F  CEX3F  CEX4F  CEX5F  CEX6F  CEX7F	CEX1R CEX2R CEX3R CEX4R CEX5R CEX5R CEX6R	1 x 44μL each 1 x 110μL each
			HLA-C MIX	1 x 880μL	CEX2F  CEX3F  CEX4F  CEX5F  CEX6F  CEX7F	CEX2R CEX3R CEX4R CEX5R CEX6R	

Page 5 of 22 For Research Use Only

Kit	Catalogue No	Σ	PRE-PCR Contents <sup>†</sup> (No of vials)		Pe	OST-PCR Conter (No of vials)	nts
Class II	1	1					
HLA-DRB1	HH-PD5.2-5(20)	20 tests	DNA POL – DRB1 HLA-DRB1 MIX	1 x 10μL 1 x 370μL	DRB1EX2F DRB1EX3R-2	DRB1EX2R-2 RB-TG344-R	1 x 44μL each
	HH-PD5.2-5(50)	50 tests	DNA POL – DRB1  HLA-DRB1 MIX	1 x 20μL 1 x 920μL	DRB1EX2F  DRB1EX3R-2	DRB1EX2R-2 RB-TG344-R	1 x 110μL each
	LG-PD5.2-7(20)	20 tests	DNA POL – DRB1 HLA-DRB1 MIX	1 x 10μL 1 x 370μL	DRB1EX2F  DRB1EX3F-7  RB-TG344-R	DRB1EX2R-2 DRB1EX3R-7	1 x 44μL each
	LG-PD5.2-7(50)	50 tests	DNA POL – DRB1 HLA-DRB1 MIX	1 x 20μL 1 x 920μL	DRB1EX2F  DRB1EX3F-7  RB-TG344-R	DRB1EX2R-2 DRB1EX3R-7	1 x 110μL each
HLA-DQB1	PQ-PD6.2-2(20)	20 tests	DNA POL – DQB1 HLA-DQB1 MIX	1 x 10μL 1 x 370μL	DQB1EX2F DQB1EX3F	DQB1EX2R DQB1EX3R	1 x 44μL each
	PQ-PD6.2-2(50)	50 tests	DNA POL – DQB1 HLA-DQB1 MIX	1 x 20μL 1 x 920μL	DQB1EX2F DQB1EX3F	DQB1EX2R	1 x 110μL each

Page 6 of 22 For Research Use Only

Kit	Catalogue No	Σ	PRE-PCR Contents <sup>†</sup> (No of vials)		POST-PCR Cont (No of vials)	
	AN-PD6.2-3(20)	20 tests	DNA POL – DQB1 HLA-DQB1 MIX	1 x 10μL 1 x 370μL	DQB1EX2F DQB1EX2R-3 DQB1EX3F DQB1EX3R	1 x 44μL each
	AN-PD6.2-3(50)	50 tests	DNA POL – DQB1 HLA-DQB1 MIX	1 x 20μL 1 x 920μL	DQB1EX2F DQB1EX2R-3 DQB1EX3F DQB1EX3R	1 x 110μL each
HLA-DPB1	HH-PD10.1(20)	20 tests	DNA POL – DPB1 HLA-DPB1 MIX	1 x 10μL 1 x 370μL	DPB1EX2F DPB1EX2R	1 x 44μL each
	HH-PD10.1(50)	50 tests	DNA POL – DPB1 HLA-DPB1 MIX	1 x 20μL 1 x 920μL	DPB1EX2F DPB1EX2R	1 x 110μL each
	KD-PD10.2-1(20)	20 tests	DNA POL – DPB1 HLA-DPB1 MIX	1 x 10μL 1 x 370μL	DPB1EX1F DPB1EX1R  DPB1EX2F DPB1EX2R  DPB1EX3F DPB1EX3R  DPB1EX4F DPB1EX4R  DPB1EX5F DPB1EX5R  PB-AG341-R	1 x 44μL each

Page 7 of 22 For Research Use Only

Kit	Catalogue No	Σ	PRE-PCR Contents <sup>†</sup> (No of vials)		PC	OST-PCR Conte (No of vials)	nts
	KD-PD10.2-1(50)	50 tests	DNA POL – DPB1 HLA-DPB1 MIX	1 x 20μL 1 x 920μL	DPB1EX1F DPB1EX2F DPB1EX3F DPB1EX4F DPB1EX5F PB-AG341-R	DPB1EX1R DPB1EX2R DPB1EX3R DPB1EX4R DPB1EX5R	1 x 110μL each

†The PRE-PCR kit contains a vial of a locus-specific PCR mix (e.g. HLA-A MIX ) consisting of PCR buffer, dNTPs, MgCl<sub>2</sub>, and locus specific PCR primers, along with a single vial of DNA polymerase (e.g. DNA POL – HLA-A ).

The POST-PCR kit contains sequencing primers (e.g. AEX1F )

## **Storage Requirements**

The PRE- and POST-PCR boxes may be separated and stored in designated PRE- and POST-PCR freezers. When stored at -20°C (temperature range of -15°C to -25°C is acceptable), the kit components can be used until the expiry indicated on the outer kit containers and can tolerate up to 25 freeze-thaw cycles.

To maintain optimal kit performance, the kit components should be removed from the -20°C storage location and thawed rapidly at room temperature before use. The kit components, with the exception of the polymerase, should then be gently vortexed to ensure that the components of each tube are appropriately mixed after thawing. After use, the kits/components should be returned immediately to -20°C.

## Materials, Reagents and Equipment Not Supplied

#### **PCR**

- 1. Sterile water
- 2. Electronic or mechanical pipettes and aerosol-resistant tips
- 3. Thermal cycler with heated lid

These kits have been validated using the following thermal cyclers:

MJ Research PTC 225 DNA Engine DYAD™, Applied Biosystems™ by Life Technologies™ Veriti™ Thermal cycler Gene Amp® PCR System 9700, and Eppendorf Mastercycler® Pro.

#### Use of other thermal cyclers with these kits requires validation by the user.

- 4. 0.2mL thin-walled thermal cycling reaction tubes (8 well strips or 96 well plates). Use those recommended for use with your thermal cycler.
- 5. Sterile 1.5mL tubes
- 6. Sterile work area such as biological safety cabinet or hood.
- 7. Table top centrifuge with plate adapters and capacity to reach 2500 x g
- 8. Vortex

#### **Agarose Gel Electrophoresis**

- 9. Agarose gel electrophoresis apparatus
- 10. 1% agarose (molecular biology grade) TBE gel containing  $0.1\mu g/mL$  ethidium bromide.
- 11. Loading buffer
- 12. PCR Marker suitable to cover range of 300 1300 bp
- 13. UV transilluminator

#### **Purification of PCR Product**

- 14. ExoSAP (USB® ExoSAP-IT® Products Cat No 78200 for 100 reactions or Illustra<sup>TM</sup> ExoProStar<sup>TM</sup> Cat No US77702 for 100 reactions)
- 15. 2mM MgCl<sub>2</sub> (Available for purchase from CareDx Pty Ltd, product code MgCl<sub>2</sub>-1.0(50) or MgCl<sub>2</sub>-1.0(3000))
- 16. Shaker

The use of alternative PCR purification techniques requires validation by the user prior to use.

#### **Sequencing Reaction**

- 17. BigDye® Terminator Cycle Sequencing Kit v3.1 or v1.1, Applied Biosystems<sup>TM</sup> by Life Technologies<sup>TM</sup>.
- 18. 5x Sequencing Reaction Buffer (CareDx Pty Ltd, product code SEQ BUF-2.0(400) or SEQ BUF-2.0(5000)) or BigDye® Terminator v3.1 or v1.1 5X Sequencing Buffer, Applied Biosystems<sup>TM</sup> by Life Technologies<sup>TM</sup>.

#### **Purification of Sequencing Reaction Products**

- 19. 125mM EDTA, pH8.0 (Available for purchase from CareDx Pty Ltd, product code EDTA-3.0(200) or EDTA-3.0(5000)).
- 20. Absolute and 80% Ethanol. Each run requires freshly prepared 80% ethanol consisting of absolute ethanol and sterile water. DO NOT USE DENATURED ETHANOL (also known as methylated spirits in some countries).

The use of alternative sequencing purification techniques requires validation by the user prior to use.

#### **Denaturation and Electrophoresis of Sequencing Reaction Products**

- 21. Hi-Di<sup>TM</sup> Formamide, Applied Biosystems<sup>TM</sup> by Life Technologies<sup>TM</sup>, product code 4311320
- 22. Automated DNA Sequencer and accessories (eg Applied Biosystems<sup>™</sup> by Life Technologies<sup>™</sup> ABI Prism® 3730), including data collection and software.
  - These kits have been tested and validated on the Applied Biosystems<sup>TM</sup> by Life Technologies<sup>TM</sup> 3100, 3730 and 3730xl capillary sequencers and software.
  - The use of other denaturation techniques and sequencing platforms requires validation by the user prior to use.
- 23. HLA Sequencing Analysis Software (e.g. ASSIGN<sup>TM</sup> SBT, version 3.6+ or higher, CareDx Pty Ltd).

## Sample Requirements

- 1. Sterile water (negative/ no template control)
- 2. High molecular weight human genomic DNA (concentration range of  $20-100 \text{ng/}\mu\text{L}$  in Tris/EDTA buffer and OD<sub>260/280</sub>> 1.8) extracted from ACD or EDTA anticoagulated whole blood specimens. Do NOT use whole blood specimens containing heparin.



- This kit must be used by trained and authorized laboratory personnel.
- All samples, equipment and reagents must be handled in accordance with good laboratory practice. In particular, all patient material should be considered as potentially infectious. The use of gloves and laboratory coats is strongly

recommended. Handle and dispose of all sample material according to local and national regulatory guidelines.

- There are NO dangerous substances contained in any of the kit components.
- Do NOT use reagents beyond their expiration date.
- The use of kit components from different kit batches is NOT recommended. Such use may affect the assay's performance.
- Use of reagents not included in this kit or not listed under "Materials, Reagents and Equipment Not Supplied" (e.g. alternative *Taq* DNA polymerases) is NOT recommended. Such use may affect the performance of the assay.
- Care should be taken to prevent cross-contamination of DNA specimens. Change tips between DNA specimens wherever possible.
- Pre- and Post-PCR activities must be strictly physically separated. Use specifically designated equipment, reagents and laboratory coats.
- Ethidium bromide is a potential carcinogen. Protective gloves must always be used when preparing and handling gels. Dispose of ethidium-bromide gels and buffers according to local and national guidelines.
- While viewing and photographing agarose gels under UV light, always avoid direct exposure and use appropriate UV-blocking face protection, disposable gloves and laboratory coats.

#### **Procedure**

#### 1. PCR

- 1.1. A separate PCR reaction will need to be set up for each locus to be amplified, and for each individual sample to be tested. Each run should include appropriate positive control/s of known genotype, and at least one negative control for each locus being amplified.
- 1.2. Prepare a fresh solution of PCR master mix each time a PCR is performed. Quickly thaw the locus-specific PCR mix at room temperature. Once thawed, vortex briefly.
- 1.3. Dispense the required volume of PCR mix and DNA polymerase into a sterile tube for the number of samples to be tested (refer to Table 1 below for the volume per reaction). Pulse vortex the solution 3-4 times.

Locus	A	В	C	DRB1	DQB1	DPB1
Locus-specific PCR Mix	16μL	16μL	16μL	16.7μL	16.7μL	16.7μL
e.g. HLA-A MIX						
DNA Polymerase	1μL	1μL	1μL	0.3μL	0.3μL	0.3μL
e.g. DNA POL – HLA-A						

Table 1: Composition of the master mix required per sample.

- 1.4. Dispense 17µL of the master mix into each reaction well.
- 1.5. Add  $3\mu L$  of sample DNA or appropriate positive control/s to each reaction well. Add  $3\mu L$  of sterile water to the negative control reaction well.
- 1.6. Seal the reaction wells. Mix gently by vortexing and centrifuge briefly.
- 1.7. Place the reaction wells into a thermal cycler and run according to the thermal cycling conditions below.

- 1.8. Amplification takes approximately 2.5 hours to complete.
- 1.9. When the PCR is completed, remove the reaction wells/plate from the thermal cycler and either proceed directly to gel electrophoresis or store at 4°C until required.

**NOTE:** Purification of amplicons by ExoSAP treatment should occur within 24 hours of completion of PCR.

#### 2. Agarose Gel Electrophoresis

2.1. Confirm successful amplification by agarose gel electrophoresis using  $2\mu L$  of each PCR product combined with  $5\mu L$  loading buffer (alternative volumes of loading buffer should be validated prior to use). The use of 1% agarose gels is recommended.

2.2. The number and expected sizes of the resultant amplicons will vary according to the locus and sample genotype. Expected PCR amplicon sizes are indicated in Table 2.

Locus	Expected band sizes	
HLA-A	≈ 2 kbp	
HLA-B	≈ 2 kbp	
HLA-C	$\approx 1.1 \text{ kbp}$ and 1.4 kbp	
HLA-DRB1	$\approx 450 \text{ bp} - 850 \text{ bp}$	(HH-PD5.2-5)
	$\approx 630 \text{ bp} - 980 \text{ bp}$	(LG-PD5.2-7)
	Banding pattern will vary presence of specific allele group	
HLA-DQB1	$\approx 300$ bp and 500 bp	(PQ-PD6.2-2)
	$\approx 400$ bp and 500 bp	(AN-PD6.2-3)
HLA-DPB1	≈ 400 bp	(HH-PD10.1)
	≈400 bp, ≈780 bp and ≈1470 t	op (KD-PD10.2-1)

Table 2: Expected product sizes for each assay.

#### 3. Purification of PCR Product

**NOTE:** Purification systems other than ExoSAP-IT® or ExoProStar<sup>TM</sup> (e.g. Agencourt® AMPure® XP or column-based systems) can be used to purify these PCR products. It is strongly recommended that users validate these procedures before proceeding. If ExoSAP-IT® is to be used it is recommended that users follow the procedure described below.

3.1.Prepare a mastermix consisting of 4μL of ExoSAP-IT® or ExoProStar<sup>TM</sup> and 8μL of 2mM MgCl<sub>2</sub> per sample to be purified. Gently pulse vortex to mix. Dispense 12μL of the mastermix into the reaction well of each reactive sample. Seal the wells, vortex and then either place on a shaker or gently vortex for 2 minutes. Centrifuge briefly before placing into the thermal cycler. Run the thermal cycler according to the following profile:

37°C - 30 mins 80°C - 15 mins 4°C - hold

3.2. Upon completion, dilute the purified product 1:4 with sterile water. This dilution step will ensure that there is sufficient template to perform the sequencing reactions and ensure that the concentration of the template is sufficient to produce good quality sequence data.

**NOTE:** A higher dilution factor (e.g. 1:8) may be required if consistently high signals and associated noise and artefacts are observed. Weaker PCR products may require a lower dilution factor.

3.3. ExoSAP treated samples may be stored at 4°C until ready for use. These samples can be stored at 4°C for up to a week before use, but should be stored at -20°C for long term storage.

#### 4. Sequencing Reaction

**NOTE:** In instances where heterozygous ambiguities are to be resolved with hemizygous sequencing primers such as HARPS<sup>®</sup>, please refer to the OLERUP SBT<sup>TM</sup> HARPS<sup>®</sup> Instructions for Use.

4.1. Table 3 lists the sequencing primers that are to be used for each locus.




Table 3: Sequencing primers provided for use for each locus.

†RB-TG344-R is a HARP<sup>®</sup> directed to the codon 86 dimorphism. Its use is optional. \*PB-AG341-R is a HARP<sup>®</sup> directed to the codon 85 dimorphism in DPB1. Its use is optional.

^DRB1EX3R-2 is a DRB1 sequencing primer which behaves similar to a HARP and is designed to sequence the following allele groups: \*03, \*08, \*11, \*12, \*13, \*14, \*15 and \*16. This primer will produce either heterozygous, hemizygous, or no sequencing data depending on the genotype of the sample being typed. When analysing DRB1EX3R-2 data in Assign™ against the DRB1-FullX2 reference, the resulting exon 3 data will be analysed in a separate layer and will allow resolution of a number of allele ambiguities in exon 3, such as the DRB1\*14:01 vs \*14:54 ambiguity. Its use is optional depending on the typing strategy used by the laboratory. This is not applicable to the LG-PD5.2-7 kits as bi-directional sequencing for exon 3 is available.

4.2. Prepare a fresh solution of sequencing primer mix on ice each time a sequence reaction is performed. The composition and volumes for the mix indicated below are **per sample.** 

Component	Volume
Sequencing primer	2μL
Sterile water	11.5μL
BigDye® Terminators	1μL
5x Seq Rxn Buffer	3.5µL

- 4.3. Mix each sequencing reaction mixture gently by pulse vortexing.
- 4.4. Dispense 18µL of the sequencing reaction mix into each appropriate reaction well.

**NOTE:** For runs which involve few samples with many sequencing primers, it is acceptable to dispense the sequencing primer  $(2\mu L)$  directly into the individual reaction wells. A master mix may then be created composing of sterile water, BigDye<sup>®</sup> Terminators and 5x Seq Rxn Buffer, of which 16uL is to be dispensed into each reaction well. It is strongly recommended that use of this alternative procedure is validated by the user prior to implementation.

4.5. Add 2µL of purified PCR product to each appropriate well.

**NOTE:** Care must be taken to prevent cross-contamination of sequence reactions.

- 4.6. Seal the reaction wells, mix gently and centrifuge briefly to ensure that the contents are located at the base of each reaction well.
- 4.7. Place the reaction wells into a thermal cycler and run according to the following profile:

	Number of cycles	Temperature and time
=	25	96°C - 10 sec 50°C - 5 sec 60°C - 2 min
	1	4°C - hold

4.8. Once the program is complete, remove the reaction wells/plate from the thermal cycler and either proceed directly to purification of the reaction products or store in the dark at 4°C until required. It is recommended that samples are purified and run on the DNA sequencer within 24 hours.

### 5. Purification of Sequencing Reaction Products

**NOTE**: Purification of the reaction products may be carried out by procedures other than the ethanol precipitation method described here. It is strongly recommended that users validate these procedures before proceeding.

- 5.1. Briefly centrifuge the reaction wells/plates before proceeding. If reusable lids/caps have been used during thermal cycling, label the lids/caps to avoid cross-contamination.
- 5.2. Carefully remove the seals.
- 5.3. To each reaction well add  $5\mu L$  of 125mM EDTA, pH8.0. Ensure that the EDTA reaches the base of the reaction well.
- 5.4. Add 60µL of 100% ethanol to each reaction well. Seal the wells/plate and vortex briefly but thoroughly to ensure thorough mixing.

- 5.5. Pellet the extension products by centrifuging at 2000g for 45 minutes. **IMMEDIATELY PROCEED TO THE NEXT STEP**. If this is not possible, recentrifuge for an additional 10 minutes before proceeding.
- 5.6. Remove the seals to the reaction wells and discard the supernatant by inverting the reaction wells onto paper towel or tissues.
- 5.7. Place the inverted reaction wells and paper towel or tissue into the centrifuge. Centrifuge at 350g for 1 minute to remove any residual supernatant.
- 5.8. Remove the reaction wells from the centrifuge and place in an upright position on the work bench. Discard the paper towel or tissues.
- 5.9. Prepare fresh solution of 80% ethanol with absolute ethanol and sterile water.
- 5.10. Add 60µL of 80% ethanol to each well. Reseal the wells and vortex briefly.
- 5.11. Spin at 2000g for 5 minutes.
- 5.12. Repeat steps 5.6 and 5.7.
- 5.13. Remove the reaction wells from the centrifuge and discard the paper towel. Reseal the reaction wells and proceed to the denaturation step. Otherwise store at -20°C in the dark. It is recommended that the extension products are run on the DNA sequencer within 24 hours of setting up the sequencing reactions.

#### 6. Denaturation & Electrophoresis of Sequencing Reaction Products

**NOTE**: The procedure for the denaturation of extension products in Hi-Di<sup>TM</sup> Formamide described here may not be necessary if purification procedures other than the ethanol precipitation have been used. It is strongly recommended that users validate alternative procedures before proceeding.

- 6.1. Add 12µL of Hi-Di™ Formamide to each reaction well. Vortex and centrifuge the wells/plate briefly.
- 6.2. Incubate the reaction wells at 98°C for 5 minutes. Following incubation, ensure that the reaction wells are cooled quickly to room temperature (e.g. place on ice or use the thermal cycler to perform the denaturation and cooling steps) before being placed on the sequencer. If it is not possible to run the plates immediately, store at 4°C until required.

**NOTE:** Ensure that there are no air bubbles in the reaction wells. These can enter and damage the capillary.

- 6.3. Load the reaction wells/plate onto the automated sequencer and prepare the data collection file according to the sequencer manufacturer specifications.
- 6.4. The following instrument parameters have been validated by the manufacturer using Big Dye® Terminator Sequencing Kit v3.1 and POP-7<sup>TM</sup>. These parameters may require user validation for other polymers, sequencing chemistries and instruments. Please refer to the appropriate instrument user's manual for detailed instructions and guidance (e.g. ensure that the dye set setting is appropriate for the chemistry used, for example v1.1 Big Dye® Terminator sequencing chemistry will require a different dye set).

Parameter	Setting
Dye set	Z_BigDyeV3

Mobility file KB\_3730\_POP7\_BDTV3

Basecaller KB.bcp

Run Module Regular FastSeq50\_POP7

Injection time 15 sec Run time 3000 sec

6.5. Use the instrument's data collection software to process the raw collected data and create the sequence files. Please refer to the appropriate instrument user's manual for detailed instructions and guidance.

#### 7. Editing and analysis of electropherograms

The OLERUP SBT<sup>TM</sup> kits were developed and validated using the OLERUP ASSIGN<sup>TM</sup> SBT software developed by CareDx Pty Ltd. Users are recommended to use ASSIGN SBT 3.6+ and higher as these versions of the software utilise setting and reference files specifically designed for the OLERUP SBT<sup>TM</sup> typing kits and HARPS<sup>®</sup>. For more details in relation to the operation of these software please refer to the applicable user manuals available for download on the Olerup website (<a href="http://www.olerup.com">http://www.olerup.com</a>).

The sequencing based typing data generated using the OLERUP SBT<sup>TM</sup> typing kits should be analysed against the following ASSIGN<sup>TM</sup> reference files which are provided by CareDx Pty Ltd:

_	Assay	<b>Product Code</b>	Assign Reference File
_	OLERUP SBT™ HLA-A	XH-PD1.1-2	A.xml
	OLERUP SBT™ HLA-B	BS-PD2.1-2	B.xml
	OLERUP SBT™ HLA-C	HH-PD3.2-2	C.xml or Cw.xml
	OLERUP SBT™ HLA-DRB1	HH-PD5.2-5	DRB1-FullX2.xml
		LG-PD5.2-7	527_DRB1.xml
	OLERUP SBT™ HLA-DQB1	PQ-PD6.2-2	DQB1.xml
		AN-PD6.2-3	623_DQB1.xml
	OLERUP SBT™ HLA-DPB1	HH-PD10.1	DPB1.xml
		KD-PD10.2-1	DPB1.xml

#### **Performance Characteristics**

CareDx Pty Ltd's OLERUP SBT<sup>TM</sup> kits are locus specific assays. Sequence analysis of PCR and sequencing primer sites and performance evaluation has not identified any common and well documented alleles that are not amplified through the recommended use of these kits.

In most instances the use of the sequencing primers incorporated in each kit will produce a HLA typing for most samples without the need for further resolution. In those instances where heterozygous ambiguities remain, the use of resolving sequencing primers (such as OLERUP SBTTM HARPS®) is recommended.

It should be noted that mutations at amplification or sequencing primer sites are possible and may result in allele drop-out. Samples that suggest a homozygous typing result must be confirmed by alternative procedures.

#### **Limitations and Cautions**

- It is strongly recommended that these kits are validated by the user prior to implementation in the laboratory using samples whose HLA type has been determined by other molecular based procedures. In particular, any deviations from this procedure (e.g. the use of alternative PCR or DNA sequencing purification procedures) must be validated by the user prior to implementation.
- These kits have been validated using panels of samples whose genotypes cover a broad range of alleles. However, it should be noted that rare alleles and alleles with polymorphisms in amplification and sequencing primer sites may be encountered and these may not be amplified or sequenced.
- The nature of HLA sequence based typing is such that factors other than the PCR mix may result in preferential amplification or allele drop out. As a consequence, apparent homozygous typing results should be confirmed using alternative methods and/or family genotyping.
- A positive control (human DNA) and negative control (sterile water) must be included on
  every PCR run. The positive control must produce a PCR product of the appropriate size
  depending on the locus amplified and the resultant sequence must be in concordance with
  the sample's genotype. There must be no PCR products in the negative template control
  for each experiment. If a band is evident contamination may have occurred at some level
  and the run must be repeated.
- Occasionally there may be additional, fainter PCR products evident. These additional bands do not interfere with sequence results or quality.

#### License

The OLERUP SBT<sup>TM</sup> kits contain GoTaq<sup>®</sup> Hot Start Polymerase (DNA POL) which is manufactured by Promega Corporation for distribution by CareDx Pty Ltd. Licensed to Promega under U.S. Patent Nos. 5,338,671 and 5,587,287 and their corresponding foreign patents.

## **Bibliography**

- 1. Sayer D, Whidborne R, Brestovac B, Trimboli F, Witt C, Christiansen F (2001): *HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors.* Tissue Antigens **57:** 46-54.
- 2. Sayer D, Whidborne R, DeSantis D, Rozemuller EH, Christiansen F, Tilanus MG (2004). A multicentre international evaluation of single-tube amplification protocols for sequencing-based typing of HLA-DRB1 and HLA-DRB3, 4, 5. Tissue Antigens 63: 412-423.
- 3. ASSIGN<sup>TM</sup> SBT v3.6+ Operator Manual, CareDx Pty Ltd
- 4. ASSIGN<sup>TM</sup> SBT v4.7 Operator Manual, CareDx Pty Ltd
- 5. OLERUP ASSIGN<sup>TM</sup> SBT v471 Operator Manual, CareDx Pty Ltd
- 6. More information regarding the UCLA DNA Exchange Program can be found at: <a href="http://www.hla.ucla.edu/cellDNA/DNA/programInfo.htm">http://www.hla.ucla.edu/cellDNA/DNA/programInfo.htm</a>.
- 7. Current HLA alleles can be found at http://www.ebi.ac.uk/imgt/hla.

# **Troubleshooting**

Problem	Possible cause(s)	Solution
No or weak PCR product	Poor quality DNA	Assess DNA quality by gel electrophoresis. Intact DNA should be approx 3kb with little or no evidence of smearing on gel. Re-extract DNA and repeat PCR where possible.
	Insufficient quantity of DNA added to PCR.	Check concentration of DNA is between 20-100ng/μL. Reextract DNA and repeat PCR where possible.
	Presence of PCR inhibitors in genomic DNA	Avoid the use of whole blood specimens containing heparin. Re-extract DNA and repeat PCR where possible.
	DNA polymerase not added to the mastermix or insufficient mixing of mastermix prior to addition to samples.	Repeat PCR. Ensure mastermix components are added and mixed sufficiently by vortexing.
	Thermal cycling problems	Check the thermal cycling run parameters. Check the run history to ensure that the run was not terminated prematurely. Ensure that the thermal cycler is operating according to manufacturer's specifications and is regularly maintained.
	No ethidium bromide added to the gel.	Submerge the gel in a staining bath containing 1X TBE with 0.5mg/mL ethidium bromide. Destain in 1X TBE before taking gel image. Ensure ethidium bromide is added to gel prior to pouring.
	DNA samples are eluted or diluted in water that can have a slightly acidic pH.	Wherever possible use sterile water with a neutral pH.
No or weak PCR product for the exon 3-5 band for the KD-PD10.2-1 assay	Poor quality DNA	Amplification of samples of very poor quality may result in weak amplification of the exon 3-5 amplicon. Typing can still be achieved using exon 1 and 2 sequence data. Alternatively re-extract DNA and repeat PCR where possible.
Incorrect band sizes	Incorrect kit used  Incorrect thermal cycling	Check that the appropriate kit is used.  Check the thermal cycle
	program used.	parameters.

	DCD contamination	Chook the possive sentual for
Weak signal intensity of electropherograms	PCR contamination  Weak PCR product	Check the negative control for evidence of contamination. Decontaminate work area and repeat PCR. Repeat PCR to identify source of contamination. Consider using a fresh kit. If the genomic DNA of a sample appears to be contaminated, re-extract or obtain an alternative source of DNA. Check gel image. Sequencing weak PCR bands is NOT recommended as the sequence quality may be insufficient for
	T CC:	SBT. Consider using a lower dilution factor (e.g. 1:2, 1:3) after PCR purification.
	Insufficient reaction products applied to sequencer	Check sequencer parameters. Injection time and voltage may need to be increased.
	Problems during purification of sequencer products	Use extreme care when discarding the supernatant as it may dislodge the pellet.
Signal intensity is too high (Presence of high fluorescent peaks – artefacts)	Too much PCR product	Check the gel image. Consider using a higher dilution factor following PCR purification. Check the amount of DNA polymerase used in the PCR.
	Too much reaction products applied to sequencer.	Check instrument parameters. Consider reducing the injection time and voltage.
Noisy baseline (high background)	Contaminated PCR product	Refer to corrective actions listed above.
	Amplification of closely related HLA genes	Check thermal cycling parameters.
	Poor PCR purification	Ensure ExoSAP treatment is undertaken according to kit's user instructions. Ensure that the PCR mixture is mixed thoroughly with enzyme. Consider using ExoSAP following the manufacturer's procedure (increasing the amount of enzyme), or consider an alternative purification technique.
	Contaminated sequencing reactions	Ensure that all steps are taken to prevent cross contamination. Change pipette tips wherever possible. Add liquids at the top of the

		reaction wells. Prevent aerosols.
	Contaminated sequencing primer	Check sequence quality of the other sequencing primers and other samples using the same primer.  Consider using a fresh aliquot of sequencing primer.
	Contaminated dye terminator mix or sequencing buffer	Repeat sequencing with fresh aliquot of reagents.
	Poor purification of sequencing products.	Repeat sequencing and ensure that purification is undertaken according to manufacturer's instructions.
Presence of Dye blobs	Poor purification of sequencing products	Purify products according to kit instructions. Ensure products are washed sufficiently with 80% ethanol.

### **Related Products**

ASSIGN<sup>TM</sup> SBT V3.6+ Product code: CGX0036+

ASSIGN<sup>TM</sup> SBT V4.7 Product code: CGX00470

OLERUP ASSIGN<sup>TM</sup> SBT V471 Product code: CGX00471

## **OLERUP SBT<sup>TM</sup> HARPS®**

For full product list, please refer to the OLERUP SBT<sup>TM</sup> HARPS<sup>®</sup> Instructions for Use.

# **OLERUP SBT<sup>TM</sup> HLA Typing Kits**

AN-PD11.0-0(20) OLERUP SBT $^{TM}$  HLA-DRB3 kit (20 and 50 tests) AN-PD11.0-0(50)

AN-PD12.0-0(20) OLERUP SBT<sup>TM</sup> HLA-DRB4 kit (20 and 50 tests)

AN-PD12.0-0(50)

AN PD13.0.0(20) OLEDLID SETTM HLA. DRR5 kit (20 and 50 to

AN-PD13.0-0(20) OLERUP SBT™ HLA-DRB5 kit (20 and 50 tests) AN-PD13.0-0(50)

LC-PD2.9(20) OLERUP SBT<sup>TM</sup> HLA-B57 kit (20 and 50 tests)

LC-PD2.9(50)

# **General Purpose Laboratory Reagents**

 $MgCl2-1.0(50) \hspace{1.5cm} 2mM \hspace{1.5cm} MgCl_2$ 

MgCl2 - 1.0(3000)

SEQ BUF -2.0(400) 5x Seq Rxn Buffer

SEQ BUF -2.0(5000)

EDTA – 3.0(200) 125mM EDTA, pH8.0

EDTA - 3.0(5000)

Please contact your local distributor for further details.

## **Contact Information**

#### Manufacturer

CareDx Pty Ltd PO Box 1294 Fremantle 6959 Western Australia Australia

Tel: +61-08-9336-4212 email: olerup-aus@caredx.com Website: www.olerup.com

For ordering details, please refer to the Olerup website (<a href="http://www.olerup.com">http://www.olerup.com</a>).

## **Method history**

Version	Date	Modification	Authorized by
1.0	04/10/2017	Drafted from version 16.0 of IFU under previous manufacturer and product name. ISSUED by L. Westwood	L. Westwood

# Authorship and approvals

Author signs to confirm technical content				
Prepared by:	Job title:	Signature:	Date:	
Subject matter expert reviewer signs to confirm technical content				
Reviewed by:	Job title:	Signature:	Date:	
Quality representative signs to confirm document complies with quality management system				
Authorised by:	Job title:	Signature:	Date:	
Document review date				